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INTRODUCTION
Respiratory syncytial virus (RSV) outbreaks represent the major cause of serious lower respiratory tract infection (LRTI) in healthy infants, and are related to a more severe and often fatal disease in high-risk patients. [1] [2] [3] Risk factors for severe RSV disease in pediatric populations include prematurity, congenital heart disease, chronic lung disease and immunocompromised states such as hematological malignancies or hematopoietic SCT (HSCT). 4 Ribavirin alone or in combination with immunomodulators is the only antiviral treatment approved by the Food and Drug Administration (FDA, USA) for the treatment of RSV infections. 5 Its efficacy remains controversial due to the unavailability of data based on welldesigned controlled trials. That is why no consensus concerning the most effective approach has been achieved. 6 Ribavirin is available in aerosol, i.v. and oral formulations. Aerosolized ribavirin has been the most widely used formulation, especially among adult HSCT patients. 6 Currently, it is the only approved therapy for RSV infection among high-risk infants and young children. Contrary to the available information regarding aerosolized formulations of ribavirin, there is a paucity of published studies using i.v. ribavirin in adults, and very few single reports on pediatric patients. There are potential advantages of i.v. drug administration: it prevents problems related to drug handling when administered in aerosol form, such as possible teratogenic exposure of caregivers and nurses and the lack of need for special air-flow and room conditions. These disadvantages of the aerosolized administration of rivabirin, together with the scanty information on the efficacy, would justify the design of new studies evaluating the i.v. administration of the drug.
The present study reports our experience on the use of i.v. ribavirin with or without intravenous immunoglobulin (IVIG) in pediatric HSCT recipients. The approval from the ethics committee of the institution and informed consent were previously obtained.
PATIENTS AND METHODS
The diagnosis of RSV infection was established by immune chromatography tests from respiratory secretions (nasopharyngeal aspirate, nasopharyngeal washing, tracheobronchial aspirate or bronchoalveolar lavage fluid); the results were available within 24 h. This diagnostic test for RSV infection shows a median sensitivity and specificity of 87.7% (86.4-91.7%) and 94% (90.2-99.2%), respectively, as compared with other reference tests. 7 The institutional policy at our Hematology department was to check RSV, influenza A and B, and H1N1 influenza (the latter only at outbreaks) in respiratory secretions of all patients undergoing hematopoietic SCT showing upper and/or lower acute respiratory symptoms: fever, rhinorrhea, progressive cough and/or dyspnea. Testing for influenza, RSV and parainfluenza is considered to be a first priority according to the fourth European conference on infections in leukemia (ECIL-4) guidelines. 8 LRTI was defined as either hypoxemia or new pulmonary infiltrates or consolidation on chest radiograph or chest CT scan together with the identification of RSV in respiratory secretions. An upper respiratory tract infection (URTI) was defined as the detection of RSV from upper respiratory tract fluid specimens together with symptoms from the upper respiratory tract (nose, throat): rhinorrhea, pharyngitis, nasal or sinus congestion or cough.
Imaging tests were routinely done in patients with RSV detection and respiratory tract infectious disease except from one individual decision.
Intravenous ribavirin was administered in cases of RSV infection in allo-SCT recipients under immunosuppressive treatment, and in auto-SCT patients within the first 4 months after transplant. Weight-adjusted i.v. dosages consisted of one daily dose of 15-25 mg/kg divided in three doses, for a period of 7-14 days for URTI and 7-21 days for LRTI, respectively. The addition of IVIG is reserved for severe LRTI-RSV or pneumonitis.
The study selection criteria in the literature review presented in Table 3 was based on MEDLINE/Pubmed database querying for articles using theses-associated search terms: ribavirin and RSV and BM or SCT. We excluded articles on prophylaxis. References from pertinent articles were examined for additional content.
RESULTS

Patient characteristics
A total of six pediatric patients undergoing HSCT had nine episodes of RSV infection. RSV episodes were analyzed out of 43 HSCT performed from January 2010 through February 2012 (21% incidence). Three patients received HSCT from unrelated donors (BM, cord blood and peripheral blood, respectively), two other patients received an HLA-identical sibling HSCT and one patient underwent autologous transplantation due to high-risk neuroblastoma. Three patients developed a second RSV episode, 2, 4 and 5 months after the first one, respectively. On account of this long interval as well as the complete resolution of symptoms in that period of time, these were considered as separate episodes. The median age at the time of diagnosis was 58 months (range 21-82). Other patient characteristics are summarized in Table 1 .
Clinical diagnosis and laboratory parameters Diagnosis of RSV infection was performed at a median of 41 days after transplantation (range from À 8 to þ 120 from HSCT). Four episodes were identified in the pre-engraftment period-while they were receiving the conditioning regimen or previous to engraftment-three episodes were detected within the first 100 days post-transplantation (one under engraftment failure) and two patients were identified at 4100 days after HSCT ( Table 1) .
The detection of RSV Ag was performed in nasopharyngeal aspirate in eight episodes. The other one was detected in a tracheal aspirate.
Four patients developed LRTI according to previously mentioned criteria. Two patients presented with severe respiratory distress due to RSV-related pneumonitis requiring invasive mechanical ventilation for 2 and 14 days, respectively (episodes 1 and 6). Concerning imaging data in patients with LRTI, two imaging patterns were found: bilateral interstitial pneumonia and diffuse infiltrative lung disease with ground-glass opacity (Table 2) .
Imaging testing was not performed at episode 7 because of the scanty symptoms, being afebrile and eupneic in an isolation room. In this case, the individual decision was to delay the imaging test waiting for clinical response and close monitoring.
Five patients presented with URTI symptoms without clinical lower respiratory tract involvement.
Median lymphocyte and neutrophil counts at the time of diagnosis were 1.2 (range 0.1-3.4) and 2.7/mL (range 0-9.6), respectively ( Table 2) . One case occurred during the period of aplasia after the conditioning regimen. GVHD was not documented in any patient.
Treatment and outcome Intravenous ribavirin was administered for a median of 12 days (range 7-21 days) in LRTI according to clinical response, with day 1 of treatment being the day of RSV detection. Two patients with LRTI received IVIG at a dose of 400 mg/kg every 48 h in addition to ribavirin treatment. No RSV-specific gamma globulin or humanized MoAb (palivizumab) was administered. All four LRTI patients showed a favorable clinical response, with 100% survival after a mean follow-up of 17 months (range [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . With regard to IVIG, our guideline was not adhered to in two patients with severe LRTI-RSV who did not receive combined therapy with IVIG (episodes 1 and 6). The reason was that they were admitted to pediatric intensive care unit and specific guideline was not established there.
Among patients with URTI, the median duration of treatment was 7 days (range 5-9 days). No progression to LRTI was documented.
No side effects were documented during ribavirin administration in any of the nine episodes. No hemolytic features and no drug-related leukopenia were recorded. Only one case of hyperbilirubinemia was noted (total serum bilirubin 1.68 mg/dL and AST 107 mU/mL), probably in the context of EBV posttransplant lymphoproliferative disorder.
Allogeneic recipients were under prophylaxis with aciclovir, trimethoprim sulfamethoxazole and fluconazole or voriconazole. No respiratory viral or fungal co-infections were documented. One patient was treated with amikacin and meropenem due to superimposed extended-spectrum beta-lactamase-producing Escherichia coli infection. All patients received empirical antibiotic treatment (cefepime or amoxicillin clavulanate) except episode 7.
As all patients responded adequately to treatment, no routine follow-up imaging was performed. For a follow-up examination, nasal secretion specimens were obtained from five cases. Median Intravenous ribavirin in pediatric hematopoietic transplantation A Molinos Quintana et al of days from treatment initiation to negative testing for RSV Ag was 14 days (range 4-24). Pulmonary sequelae in the form of peribronchiolar inflammation detected by pulmonary biopsy were described in one patient (episode 6) 15 months after RSV infection. Respiratory function test was not possible because of short age and inadequate collaboration of patients.
DISCUSSION
RSV is the major viral pathogen responsible for LRTI in young children. 3 The frequency of RSV infection in adults is about 2-17% among HSCT recipients. 6, 9, 10 This incidence is lower than that observed in the present study conducted in infants. Severity is highest in HSCT patients. Characteristics of patients were defined as severe immunodeficiency based on criteria adapted from Khanna et al. 9 All the patients were under HSCT o6 months before diagnosis of RSV infection. Two patients fulfilled only this criterion, whereas four patients fulfilled two criteria (episodes 2, 5, 6 and 7) and three patients fulfilled Xthree criteria (episodes 4, 8 and 9) because of T-cell depletion, leukopenia, lymphopenia, hipogammaglobulinemia and/or pre-engraftment period.
With regard to RSV treatment in children, the Cochrane database review focuses on healthy pediatric infants. Aerosolized ribavirin is licensed for severe RSV infections and may reduce the duration of mechanical ventilation and hospitalization as well as the long-term incidence of recurrent wheezing. However, no sufficient power to provide reliable estimates is available. 11, 12 In addition, no reviews are available for immunocompromised children. Different recommendations for ribavirin treatment have been provided, such as aerosolized, i.v. or oral applications, but no controlled clinical trials to reach treatment consensus have been conducted. 6, 13 Aerosolized ribavirin has been the most frequently used treatment for RSV after HSCT. 10 Its use has been limited on account of the lack of proven efficacy and potential toxicity to caregivers exposed to the drug, including potential teratogenicity. claustrophobia, cough, conjunctival irritation and nausea have been reported. Penetration of the aerosolized drug in the lungs is not well established, and impairment has been shown during mechanical ventilation. In this regard, obstructive respiratory distress and dyspnea have been reported in patients receiving ribavirin inhalation therapy, leading to drug discontinuation. 14 Allogeneic (3) LRTI (3) ivR (1) Combined ( Allogeneic (17) LRTI (8) URTI (9) AerR (4) ivR (1) Combined (1 This report included pediatric patients, but number is unknown. A total of 32 patients including adult and pediatric patients.
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Oral ribavirin is the least expensive form and does not require hospitalization, but its bioavailability is 30-70%. 15 Oral absorption has been shown in GVHD patients but it has not been largely determined. Finally, i.v. ribavirin has been authorized by the FDA as a result of an emergency investigational new drug application for patients with serious viral infection. 5 Findings, however, were inconclusive. ECIL-4 guidelines included an off-label use of systemic ribavirin for RSV infections. 8 Reported side effects included hemolysis, leukopenia and hyperbilirubinemia. 9, 14, 16 In our study, no related side effects were observed, which was consistent with previous studies reporting on the use of ribavirin in the hepatitis C infection setting. 17 Recently, Shah et al. 6 reviewed and summarized the use of ribavirin from 26 available studies involving adult HSCT patients infected with RSV. The authors concluded that patients receiving antiviral treatment had better outcomes than untreated patients. Although aerosolized ribavirin is largely the most commonly used formulation, the study included 40 adult patients under i.v. ribavirin from five studies conducted from 1996 to 2004, which reported a mortality of 58% among patients with LRTI infections.
To our knowledge, the management of RSV infection in HSCT pediatric patients relies on the experience reported in adult patients, mostly due to the low number of studies focused on this population. Consequently, no international consensus has been reached and pediatric patients still remain understudied. In this regard, some studies suggest improved outcomes with the addition of high-dose Ig, 18, 19 RSV-IVIG 20 or MoAb (palivizumab) 21 in children undergoing HSCT, but clear evidence of efficacy is lacking. Prophylaxis with palivizumab has been approved by the FDA in prematurity or in bronchopulmonary dysplasia, 22 but is still limited by its high cost. 23 Also, its efficacy in HSCT has not been proven yet.
Concerning RSV-related mortality, Khanna et al. 9 reviewed the literature and reported mortalities of 38% in patients with RSV-LRTI treated with aerosolized ribavirin, 43% in patients treated with the combination of ribavirin and IVIG, and 64% in patients treated with i.v. ribavirin. As pointed out by the authors, the increased mortality among patients treated with i.v. ribavirin was due to a more advanced disease status at the time of treatment. Outcomes reported in pediatric populations in the HSCT setting are summarized in Table 3 . According to our results, the use of i.v. ribavirin was associated with very good outcomes among patients undergoing HSCT.
To our knowledge, this is the first study to evaluate the safety and efficacy of early administration of i.v. ribavirin in a pediatric population in the HSCT setting. Our study was limited by its retrospective, small sample size and uncontrolled design, but nevertheless, it was conducted in a homogeneous pediatric patient population consecutively diagnosed with RSV. We conclude that, in our group of patients, i.v. ribavirin was safe, showed no RSV-related mortality and was well tolerated without associated side effects. This case series reporting on the outcome of RSV-infected pediatric HSCT recipients justifies further investigation to clarify the efficacy of i.v. ribavirin in this population.
